NCCN Guidelines Endorse FES PET for Workup of Recurrent/Meta

The National Comprehensive Cancer Network Guidelines now recommend the use of 18F-Fluorestradiol positron emission tomography in certain circumstances during the systemic staging workup for patients with recurrent or metastatic for estrogen receptor–positive breast cancer.

Related Keywords

Seattle , Washington , United States , University Of Washington , Hannahm Linden , Mark Hibberd , David Mankoff , Ge Healthcare , National Comprehensive Cancer Network , Society Of Nuclear Medicine , Fred Hutchinson Cancer Center , University Of Pennsylvania , Use Criteria , Nuclear Medicine , Molecular Imaging , Pharmaceutical Diagnostics , Practice Guidelines , Zionexa United States , 18f Fluorestradiol , Nccn , 18f Fes , Cerianna , Estrogen Receptor Positive Breast Cancer , Breast Cancer , Er Positive Breast Cancer , Pet ,